DailyIQ
|
Sector:HealthcareAll sectors
Last updated 6 minutes ago

ABCL·AbCellera Biologics Inc.

$.
-. (-.%)
After Hours
High
$6.38
Open
$6.20
Market Cap
1.72B
52W High
$6.79
Low
$5.50
P. Close
$5.61
P/E
-
52W Low
$2.33
Fwd P/E
-7.81
DailyIQ Est.
-
Technical Score (1D)
82
BUY
News Sentiment
75
BULLISH
AbCellera Biologics (ABCL) just released encouraging interim Phase 1 data for its lead antibody ABCL635, a development that has immediately bolstered investor confidence. The positive results, coupled with stronger‑than‑expected Q1 revenue growth, suggest the company’s proprietary pipeline is beginning to generate tangible returns. In addition, the board’s recent appointment of veteran clinical executive Victor Sandor signals a strategic push toward accelerated regulatory progress for in‑house programs. These factors collectively raise the likelihood that ABCL will attract further capital and potentially broaden its revenue streams beyond partner‑based discovery. The shift to proprietary drug development, highlighted in the 7‑hour‑old report, positions ABCL to capture a larger share of the menopause‑related hot‑flash market, which could drive future sales growth. For the next 1–10 trading days, traders should monitor how the market incorporates the Phase 1 data into the stock’s valuation, as the company remains well below analyst price targets. A key watch item is the upcoming data release for ABCL635, which will confirm whether the Phase 1 success translates into a robust clinical trajectory. Additionally, any updates on the company’s drug‑development pipeline or regulatory milestones will be critical in assessing the sustainability of the current upside. Finally, keep an eye on broader market sentiment toward biotech firms, as shifts in risk appetite could influence ABCL’s short‑term performance. These developments collectively underscore a pivot toward a more balanced value‑creation strategy, potentially setting the stage for diversified revenue streams in the near term.
Earnings Summary
AbCellera Biologics Inc. is a biotechnology firm focused on the discovery and development of antibody-based therapeutics, primarily targeting unmet medical needs within the United States. The company's core business centers on identifying and advancing potential drug candidates through preclinical trials, operating within the dynamic Biotechnology sector. In its most recent reported quarters, AbCellera experienced a notable revenue surge in Q4 2025, reporting $44.85 million against an estimate of $6.19 million, a significant beat. This followed a period of fluctuating revenue, with Q3 2025 at $8.96 million and Q2 2025 at $17.08 million. Earnings per share (EPS) have consistently been negative, with Q4 2025 showing a significant improvement, reporting -0.03 against an estimate of -0.1775, a substantial beat. Prior to this, Q3 2025 EPS was -0.19 (miss), Q2 2025 was -0.12 (beat), and Q1 2025 was -0.15 (miss). The company has demonstrated an inconsistent beat/miss pattern for EPS, beating estimates in 2 of the last 4 reported quarters, while revenue estimates were only provided for the last two quarters, with a significant beat in Q4 2025. Looking at the year-over-year trajectory, the Q4 2025 revenue represents a substantial increase compared to prior periods, though direct YoY comparisons are limited by the available data. The company has shown a pattern of significant revenue beats when estimates are available, particularly in Q4 2025, despite ongoing EPS misses in most quarters. Recent news indicates a significant Q1 2026 revenue increase to $8.32 million, doubling year-over-year, partly due to positive interim Phase 1 data for their ABCL635 antibody candidate. This advancement towards Phase 2 trials is a key focus. However, contrasting analyst sentiment exists, with some projecting significant upside while one firm has downgraded the stock to a 'sell' rating. Investors will be watching for further clinical updates on ABCL635 and how these developments shape AbCellera's long-term business model, alongside monitoring the impact of mixed analyst ratings on market perception.

EPS

EstBeatMiss
$-0.23$-0.17$-0.11$-0.06$-0.00Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$-0.20 - -
Q4'25$-0.18$-0.03+83.1%
Q3'25$-0.16$-0.19-17.3%
Q2'25$-0.16$-0.12+26.5%
Q1'25$-0.14$-0.15-5.3%
Q4'24$-0.15$-0.12+20.8%

Revenue

EstBeatMiss
$-2M$11M$25M$38M$51MQ4'24Q1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$6M - -
Q4'25$6M$45M+625.1%
Q3'25 - $9M -
Q2'25 - $17M -
Q1'25 - $4M -
Q4'24 - $5M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ABCL Stock Snapshot

ABCL is currently trading at $5.77, giving AbCellera Biologics Inc. a market cap of 1.72B. Today's range spans $5.50–$6.38, with shares opening at $6.20 and moving up $0.15 (2.8%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 75/100.

Over the past year ABCL has traded between $2.33 and $6.79 - the current price is +147.6% off the 52-week low and -15.0% from the high.

The data on AbCellera Biologics Inc. (ABCL) makes a clear case: BUY signal, 82/100 technical score, bullish sentiment at 75/100, price $5.77 (in the upper portion of its 52-week range). At 1.72B in Healthcare market cap, this is a name where the traditional risk/reward calculus shifts - lower liquidity means wider spreads and faster moves, but the bullish setup with sentiment confirmation reduces the probability of a failed breakout. Annual range: $2.33–$6.79.

The combination of a BUY technical signal (82/100) and bullish news sentiment (75/100) in a small-cap like ABCL (1.72B, Healthcare) creates the kind of setup that shows up in small-cap momentum screens used by growth-oriented funds. At $5.77 (in the upper portion of its 52-week range in $2.33–$6.79), the stock is not yet crowded — which means the entry risk-reward is better than it will be if the technical and sentiment setup persists and attracts wider institutional attention.